Risk of liver and cardiovascular outcomes in patients with metabolic dysfunction-associated steatohepatitis (MASH): a retrospective cohort study
MASH was associated with significantly higher risks of MALO and MACE. This highlights the clinical burden of MASH and the need for early detection and management.
Authors
- Anthony Hoovler (ORCID: https://orcid.org/0000-0002-8833-4923)
- Semiu O. Gbadamosi (ORCID: https://orcid.org/0000-0003-2048-2943)
- Jonathan Johnson (ORCID: https://orcid.org/0000-0002-9810-2771)
- Abdalla Aly
- Chi Nguyen
- Noah Webb
Institutions
- Novo Nordisk (United States) (US)
- Optum (United States) (US)
- Novo Nordisk (Italy) (IT)
- Optimum Therapeutics (United States) (US)
- Optimum Technologies (United States) (US)
Publication Details
- Journal
- Current Medical Research and Opinion
- Published
- 2026-01-02
- DOI
- https://doi.org/10.1080/03007995.2026.2635676
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00